Original Contribution

Colon/Small Bowel

The Role of an IgA/IgG-Deamidated Gliadin Peptide Point-of-Care Test in Predicting Persistent Villous Atrophy in Patients With Celiac Disease on a Gluten-Free Diet

  • The American Journal of Gastroenterology (2017) 112, 18591867 (2017)
  • doi:10.1038/ajg.2017.357
  • Download Citation
Published online:



Mucosal healing is important in celiac disease (CD) for the prevention of complications. However, obtaining duodenal biopsies is invasive, and there is currently no reliable surrogate marker for histological remission in clinical practice. We aimed to assess the role of a point-of-care test (POCT) based on IgA/IgG-deamidated gliadin peptide, in detecting persistent villous atrophy (VA) in CD.


We prospectively recruited patients with CD attending endoscopy for the assessment of histological remission. All patients had IgA-endomysial (EMA) antibodies, IgA-tissue transglutaminase (TTG) antibodies, and the POCT performed, and completed a validated dietary adherence questionnaire. A gastroscopy was performed in all patients, with four biopsies taken from the second part of the duodenum and one from the duodenal bulb. We compared the diagnostic performance of the surrogate markers against duodenal histology as the reference standard.


A total of 217 patients with CD (70% female, age range 16–83 years, median age 53 years) on a gluten-free diet (median duration 6 years) were recruited from 2013 to 2017. Eighty-five (39.2%) patients had persistent VA. The sensitivities of the POCT, TTG, EMA, and the adherence score in detecting VA were 67.1%, 44.7%, 37.7%, and 24.7% respectively (P=0.0005). The combination of the POCT and adherence score only marginally increased the sensitivity to 70.6% (59.7–80.0%).


The sensitivity of the POCT was higher than the other surrogate markers in predicting VA. A POCT may provide the additional advantage of an immediate objective assessment of mucosal healing at the time of an office-based follow-up consultation.

  • Subscribe to The American Journal of Gastroenterology for full access:



Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.


  1. 1.

    , , et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003;163:286–292.

  2. 2.

    , , et al. Seroprevalence, correlates, and characteristics of undetected coeliac disease in England. Gut 2003;52:960–965.

  3. 3.

    , , et al. Living gluten-free: adherence, knowledge, lifestyle adaptations and feelings towards a gluten-free diet. J Hum Nutr Diet 2016;29:374–382.

  4. 4.

    , , . Intentional and inadvertent non-adherence in adult coeliac disease. A cross-sectional survey. Appetite 2013;68:56–62.

  5. 5.

    , , . Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease. Aliment Pharmacol Ther 2009;30:315–330.

  6. 6.

    , , et al. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007;5:445–450.

  7. 7.

    , , et al. Etiology of nonresponsive celiac disease: results of a systematic approach. Am J Gastroenterol 2002;97:2016–2021.

  8. 8.

    , , et al. Celiac disease: management of persistent symptoms in patients on a gluten-free diet. World J Gastroenterol 2012;18:1348–1356.

  9. 9.

    , , et al. Mucosal recovery and mortality in adults with celiac disease after treatment with a gluten-free diet. Am J Gastroenterol 2010;105:1412–1420.

  10. 10.

    , , et al. Optimising delivery of care in coeliac disease—comparison of the benefits of repeat biopsy and serological follow-up. Aliment Pharmacol Ther 2013;38:1278–1291.

  11. 11.

    , , . Histologic follow-up of people with celiac disease on a gluten-free diet: slow and incomplete recovery. Am J Clin Pathol 2002;118:459–463.

  12. 12.

    , , et al. Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study. Ann Int Med 2013;159:169.

  13. 13.

    , , et al. Persistent mucosal damage and risk of fracture in celiac disease. J Clin Endocrinol Metab 2014;99:609–616.

  14. 14.

    , . Complications of endoscopy. Am J Surg 2001;181:319–332.

  15. 15.

    Committee ASoP, et al. Adverse events of upper GI endoscopy. Gastrointest Endosc 2012;76:707–718.

  16. 16.

    , , et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut 2014;63:1210–1228.

  17. 17.

    , , et al. World Gastroenterology Organisation global guidelines on celiac disease. J Clin Gastroenterol 2013;47:121–126.

  18. 18.

    , , . American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006;131:1981–2002.

  19. 19.

    , , et al. American College of G. ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013;108:656–676.

  20. 20.

    , , et al. Serum I- FABP detects gluten responsiveness in adult celiac disease patients on a short-term gluten challenge. Am J Gastroenterol 2016;111:1014–1022.

  21. 21.

    , , et al. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. Gut 2017;66:250–257.

  22. 22.

    , . Serum markers in the clinical management of celiac disease. Dig Dis. 2015;33:236–243.

  23. 23.

    , , et al. Low-dose gluten challenge in celiac sprue: malabsorptive and antibody responses. Clin Gastroenterol Hepatol 2005;3:679–686.

  24. 24.

    , , et al. Intestinal permeability and antigliadin antibody test for monitoring adult patients with celiac disease. Dig Dis Sci 2007;52:1304–1309.

  25. 25.

    , , et al. CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac disease. Am J Gastroenterol 2013;108:1344–1351.

  26. 26.

    , , et al. IgA-class transglutaminase antibodies in evaluating the efficacy of gluten-free diet in coeliac disease. Eur J Gastroenterol Hepatol 2002;14:311–315.

  27. 27.

    , , . Disappearance of endomysial antibodies in treated celiac disease does not indicate histological recovery. Am J Gastroenterol 2000;95:712–714.

  28. 28.

    , , et al. What is the role of serologic testing in celiac disease? A prospective, biopsy-confirmed study with economic analysis. Clin Gastroenterol Hepatol 2008;6:314–320.

  29. 29.

    , , . Lack of usefulness of anti-transglutaminase antibodies in assessing histologic recovery after gluten-free diet in celiac disease. J Clin Gastroenterol 2003;37:387–391.

  30. 30.

    , , et al. A prospective comparative study of five measures of gluten-free diet adherence in adults with coeliac disease. Aliment Pharmacol Ther 2007;26:1227–1235.

  31. 31.

    , , et al. A score that verifies adherence to a gluten-free diet: a cross-sectional, multicentre validation in real clinical life. Br J Nutr 2012;108:1884–1888.

  32. 32.

    , , et al. Increased detection of celiac disease with measurement of deamidated gliadin peptide antibody before endoscopy. Clin Gastroenterol Hepatol 2015;13:1278–84.e1.

  33. 33.

    , , et al. Point-of-care testing for celiac disease has a low sensitivity in endoscopy. Gastrointest Endosc 2014;80:456–462.

  34. 34.

    , , et al. Self transglutaminase-based rapid coeliac disease antibody detection by a lateral flow method. Aliment Pharmacol Ther 2006;24:147–154.

  35. 35.

    , , et al. Early diagnosis of celiac disease in IgA deficient children: contribution of a point-of-care test. BMC Gastroenterol 2014;14:186.

  36. 36.

    , , et al. Diagnostic accuracy of a new point-of-care screening assay for celiac disease. World J Gastroenterol 2013;19:5111–5117.

  37. 37.

    , , et al. Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study. BMJ 2007;335:1244–1247.

  38. 38.

    , , et al. Looking for celiac disease: diagnostic accuracy of two rapid commercial assays. Am J Gastroenterol 2006;101:1597–1600.

  39. 39.

    , , et al. The role of near- patient coeliac serology testing in the follow- up of patients with coeliac disease. Frontline Gastroenterol 2014;5:20.

  40. 40.

    , , et al. Celiac disease screening by immunochromatographic visual assays: results of a multicenter study. J Pediatr Gastroenterol Nutr 2007;45:546–550.

  41. 41.

    , , et al. Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up. Dig Dis Sci 2008;53:1582–1588.

  42. 42.

    , , et al. Persistence of elevated deamidated gliadin peptide antibodies on a gluten-free diet indicates nonresponsive coeliac disease. Aliment Pharmacol Ther 2014;39:407–417.

  43. 43.

    , , et al. Use of deamidated gliadin peptide antibodies to monitor diet compliance in childhood celiac disease. J Pediatr Gastroenterol Nutr 2011;53:55–60.

  44. 44.

    , , et al. Application of deamidated gliadin antibodies in the follow-up of treated celiac disease. PLoS ONE 2015;10:e0136745.

  45. 45.

    , , et al. Can celiac serology alone be used as a marker of duodenal mucosal recovery in children with celiac disease on a gluten-free diet? Am J Gastroenterol 2014;109:1478–1483.

  46. 46.

    , , et al. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment Pharmacol Ther 2007;25:1237–1245.

  47. 47.

    , , et al. Coeliac disease: a histological follow-up study. Histopathology 2007;50:465–471.

  48. 48.

    , , et al. Complete recovery of intestinal mucosa occurs very rarely in adult coeliac patients despite adherence to gluten-free diet. Aliment Pharmacol Ther 2009;29:1299–1308.

Download references

Author information


  1. Academic Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield Teaching Hospitals, Sheffield, UK

    • Michelle S Lau
    • , Peter D Mooney
    • , William L White
    • , Michael A Rees
    • , Simon H Wong
    • , Matthew Kurien
    • , Nick Trott
    • , Marios Hadjivassiliou
    •  & David S Sanders
  2. Celiac Center and Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

    • Daniel A Leffler


  1. Search for Michelle S Lau in:

  2. Search for Peter D Mooney in:

  3. Search for William L White in:

  4. Search for Michael A Rees in:

  5. Search for Simon H Wong in:

  6. Search for Matthew Kurien in:

  7. Search for Nick Trott in:

  8. Search for Daniel A Leffler in:

  9. Search for Marios Hadjivassiliou in:

  10. Search for David S Sanders in:

Competing interests

Guarantor of the article: David Sanders, MBChB, MD, FACG, FRCP.

Specific author contributions: M.S.L.: data collection, analysis and interpretation of the data, statistical analysis, and drafting of the manuscript. P.D.M.: data collection, and analysis and interpretation of the data. W.L.W., M.A.R., and S.H.W.: data collection. N.T., D.L., M.H., and M.K.: revision of the manuscript. D.S.S.: study concept and design, revision of the manuscript, and study supervision. All authors have approved the final draft submitted.

Financial support: None.

Potential competing interests: Professor Sanders has received educational research grants from Dr Schaer (a gluten-free food manufacturer) and Tillotts Pharma (distributor of a POCT for CD) for investigator led studies. Dr Schaer and Tillott’s Pharma did not have any input in the study design, access to study data, interpretation of the findings, or drafting of the manuscript. Daniel Leffler is a Medical Director at Takeda Pharmaceuticals. Takeda Pharmaceuticals did not have any input in the study design, access to study data, interpretation of the findings, or drafting of the manuscript. All other authors declare no conflicts of interest.

Corresponding author

Correspondence to Michelle S Lau.